



Prescribing Basal-Bolus Made Easy

All commercially insured patients have access to V-Go and V-Go is covered on Medicare Part D

How to Prescribe

Send Prescriptions to Patients' Preferred Pharmacy

1

Select the appropriate V-Go Dose Option



Example Prescription For:
V-Go Device

Rx: V-Go 20, 30 or 40

Dispense: #1 box of 30 V-Go devices for 30 days

Sig: Use 1 V-Go every 24 hours as directed

SIGNATURE _____ DATE _____



2

V-Go is filled with a U-100 Rapid-Acting Insulin



Example Prescription For:
Insulin to Fill V-Go 30

Rx: U-100 rapid-acting insulin

Dispense: #3 x 10 mL vials

Sig: Administer up to _____ U/day

**Per FDA Labeling
Required Vials/Month:**

#2 x 10 mL vials required for V-Go 20
#3 x 10 mL vials required for V-Go 30
#3 x 10 mL vials required for V-Go 40



The majority of V-Go prescriptions are filled by simply sending the prescription to the patients' preferred pharmacy.

mannkind



Initiating V-Go for Basal-Bolus

V-Go provides a consistent 24-hour continuous basal infusion and on-demand bolus dosing with meals

V-Go is available in 3 dosing options¹

| Dose | Basal Rate | Mealtime Insulin | Available Units for Dosing/24 Hr |
|---------------|--------------------------------|------------------|----------------------------------|
| VGO 20 | 20 Units 0.83 U/hour | 36 Units | 56U |
| VGO 30 | 30 Units 1.25 U/hour | 36 Units | 66U |
| VGO 40 | 40 Units 1.67 U/hour | 36 Units | 76U |

The Bolus Delivery Button can be clicked 18 times in every 24-hour period. 1 click= 2 units
V-Go is applied like a patch and once filled delivers a basal rate of insulin and on-demand bolus dosing.

*Individual dosing needs may vary

1. V-Go Instructions for Patient Use. DCN 2560 Rev. C 06/2022. 2. Adapted from Edelman SV, Bode BW, Bailey TS, et al. Insulin pump therapy in patients with type 2 diabetes safely improved glycemic control using a simple insulin dosing regimen. 3. Data on File. March 2024. MannKind Corporation.

Important Safety Information: If regular adjustments or modifications to the basal rate of insulin are required in a 24-hour period, or if the amount of insulin used at meals requires adjustments of less than 2-Unit increments, use of the V-Go Wearable Insulin Delivery device may result in hypoglycemia. The following conditions may occur during insulin therapy with V-Go: hypoglycemia (low blood glucose) or hyperglycemia (high blood glucose). Other adverse reactions associated with V-Go use include skin irritation from the adhesive pad or skin infections at the infusion site. V-Go is magnetic resonance (MR) unsafe and should be removed before having an X-ray, MRI or CT scan.

V-GO, V-GO WEARABLE INSULIN DELIVERY and MANNKIND logo are registered trademarks of MannKind Corporation
US-VGO-0134 04/2024 © 2024 MannKind Corporation

V-Go Dosing Guidance in Patients Switching from MDI^{2,3}

| | |
|----------------------|--|
| < 200 lbs | |
| VGO 20 | Start bolus dosing 3 clicks/meal |
| 200 - 250 lbs | |
| VGO 30 | Start bolus dosing 4 clicks/meal |
| > 250 lbs | |
| VGO 40 | Start bolus dosing 5 clicks/meal |

mannkind